$35.03
+4.39 (+14.33%)
Open$31.12
Previous Close$30.64
Day High$35.05
Day Low$30.86
52W High$33.60
52W Low$10.38
Volume—
Avg Volume2.13M
Market Cap2.21B
P/E Ratio—
EPS$-2.17
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-29.3% upside
Current
$35.03
$35.03
Target
$24.77
$24.77
$14.60
$24.77 avg
$27.54
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 128.04M | 140.13M | 205.11M |
| Net Income | -93,724,957 | -92,319,646 | -12,900,416 |
| Profit Margin | -73.2% | -69.5% | -6.3% |
| EBITDA | -179,615,532 | -186,751,401 | -15,864,221 |
| Free Cash Flow | — | — | -6,278,593 |
| Rev Growth | -8.6% | -8.6% | +24.6% |
| Debt/Equity | 0.19 | 0.19 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |